Bausch + Lomb Corporation (BLCO) AI Stock Analysis

9 Followers

Bausch + Lomb Corporation

(TSX:BLCO)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified Eye Health PortfolioThe company operates across three complementary eye-health categories and multiple customer channels, reducing reliance on a single product or market. Repeat contact-lens purchases, procedure-driven consumables, and pharmaceutical and OTC demand provide several durable revenue streams.

Negative Factors

Persistent Net LossesImproved operating profitability has not yet translated into consistent bottom-line earnings. The continuing net loss indicates that costs, interest, or other non-operating pressures remain material, limiting shareholder returns and leaving profitability improvement unfinished.

Bausch + Lomb Corporation (BLCO) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 7.62B
Dividend Yield: ―
Average Volume (3M): 2,136
Price to Earnings (P/E): -68.8
Beta (1Y): 1.26
Revenue Growth: 8.12%
EPS Growth: 64.80%
Country: Canada
Employees: 13,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Instruments & Supplies

Bausch + Lomb Corporation Business Overview & Revenue Model

Company Description

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a co...

Bausch + Lomb Corporation Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:21.74%|Next Earnings Date:Feb 24, 2027

Earnings Call SentimentPositive

The call was strongly positive, with broad-based revenue growth, significant adjusted EBITDA and margin expansion, record quarterly cash generation, lower leverage, raised 2026 guidance, and continued momentum across key brands and pipeline programs. The main challenges were foreign-exchange headwinds, lower surgical equipment revenue tied to the placement strategy, slower international contact-lens growth, and the ongoing development and regulatory work required for pipeline programs.

Positive Updates

Broad-Based Q3 Revenue Growth

Third-quarter revenue was $1.375 billion, up 8% on a constant-currency basis, with growth across all three segments: Pharmaceuticals increased 11%, Surgical increased 9%, and Vision Care increased 6%.

Negative Updates

Foreign Exchange Headwinds

Foreign exchange was a headwind to third-quarter revenue of approximately $6 million. The company reduced its expected full-year 2026 currency revenue tailwind to $40 million from approximately $45 million as exchange rates moderated.

Company Guidance

For 2026, with 1 quarter remaining, the company raised full year revenue guidance by $10 million to a range of $5.450 billion to $5.550 billion, reflecting full year constant currency growth of approximately 6.1% to 8.0%; adjusted EBITDA guidance was raised by $65 million to a range of $1.090 billion to $1.140 billion, implying an adjusted EBITDA margin of approximately 20.3%, about 130 basis points above the full year 2026 outlook provided at Investor Day. The company now estimates a $40 million revenue tailwind from currency, down from approximately $45 million previously; adjusted gross margin is expected to be in the range of 62.5% to 63%, R&D investment in the range of 7.5% to 8.0% of revenue, interest expense approximately $365 million, full year CapEx approximately $285 million, and the adjusted tax rate approximately 18%, slightly below the previous outlook of 19.0%. The company continues to target 3.5x leverage and a 23% EBITDA margin target in 2028.

Bausch + Lomb Corporation Risk Analysis

Bausch + Lomb Corporation disclosed 53 risk factors in its most recent earnings report. Bausch + Lomb Corporation reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Bausch + Lomb Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:BLCO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WST	78Outperform	$28.74B	46.03	21.08%	0.22%	12.60%	32.05%
ATR	67Neutral	$9.14B	34.39	10.14%	1.36%	8.97%	-34.33%
STAA	59Neutral	$1.20B	2669.00	0.15%	―	42.36%	―
COO	58Neutral	$12.09B	21.48	6.88%	―	4.73%	43.89%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	46Neutral	$13.67B	-19.09	-11.62%	0.15%	5.33%	-164.67%

* Healthcare Sector Average

Performance Comparison

TSE:BLCO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:BLCO	Bausch + Lomb Corporation	30.09	8.24	37.73%
ATR	AptarGroup, Inc.	141.72	24.86	21.27%
BAX	Baxter International Inc	25.74	7.31	39.63%
COO	Cooper Companies	62.19	-9.94	-13.78%
STAA	Staar Surgical Company	26.78	0.46	1.75%
WST	West Pharmaceutical Services, Inc.	411.30	150.71	57.83%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Bausch + Lomb Corporation AI Stock Analysis